About
Lindis Blood Care GmbH develops medical devices based on Antibody-Based Cell Removal Technology (ABCR-T) to remove tumor and immune cells from salvaged blood during cancer surgeries, enabling safer autologous blood transfusions and reducing reliance on donor blood.
Explore Lindis Blood Care GmbH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.